Understanding HCV Nonresponse and Identifying Candidates for Retreatment
Source: New Management Strategies for HCV Nonresponders and Relapsers

Module

Mitchell L. Shiffman, MD, reviews the various types of virologic response in hepatitis C virus–infected patients treated with interferon and ribavirin-based regimens and explains how to identify patients who would be good candidates for retreatment if they fail to achieve sustained virologic response.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Specify standard definitions of response and nonresponse to hepatitis C virus therapy
  • Discuss factors associated with nonresponse to hepatitis C virus therapy
  • Report criteria that may help to identify nonresponders who are good candidates for retreatment
  • Summarize data from studies of different retreatment strategies
  • Describe appropriate virologic goals of therapy for nonresponders undergoing retreatment

Topics covered include:

  • Introduction
  • Defining the Patterns of Virologic Response and Nonresponse
  • Rapid Virologic Response
  • Achieving Undetectable HCV RNA After Week 4 and Slow Virologic Response
  • Early Virologic Response and Nonresponse Virologic Patterns
  • Breakthrough and Relapse
  • Identifying Candidates for Retreatment: Null Response
  • Identifying Candidates for Retreatment: Partial Virologic Response
  • Identifying Candidates for Retreatment: Noncompliance, Medication Errors and Dose Reduction
  • Identifying Candidates for Retreatment: Failure to Recognize That Virologic Response Has Occurred
  • Identifying Candidates for Retreatment: Insufficient Treatment Duration
  • Conclusions
  • Summary of Clinical Implications
 

Faculty

  • Mitchell L. Shiffman
    MD

Credit Information

  • Release Date:
    October 04, 2007
  • Expiration Date:
    October 03, 2008
  • Physicians:
    maximum of 1.0 AMA PRA Category 1 Credit
  • Registered Nurses:
    1.0 Nursing contact hour
  • Prioritizing Patients for HCV Therapy: The Case for Treating Before Advanced Disease

    Nancy Reau MD - 9/23/2014    4 comments / Last Comment: 10/24/2014
    Despite remarkable advances in curative treatments for HCV, many patients are being denied insurance coverage, as priority access to these costly medications is given to those with advanced disease.
  • Delivering on the Promise: Maximizing SVR in the Real World

    Jordan J. Feld MD, MPH - 10/6/2014    5 comments / Last Comment: 10/30/2014
    Delivering the successes of recent HCV therapy trials to the real world will take some work, but here is how it can be achieved.
  • Are New HCV Therapies Ready for Use in Transplant Patients?

    Paul Y. Kwo MD - 7/10/2014    4 comments / Last Comment: 9/18/2014
    Paul Y. Kwo, MD, introduces some of the topics that will be discussed in an upcoming symposium in San Francisco.
  • How Does the AASLD/IDSA HCV Guidance Weigh in on Management of HIV Coinfection?

    Douglas T. Dieterich MD - 10/9/2014    1 comment / Last Comment: 10/24/2014
    There is great interest in offering coinfected patients the same opportunity for cure as monoinfected patients. The AASLD/IDSA guidance has developed recommendations aimed at maximizing cure in different populations of coinfected individuals.
  • My Take on the Guidance From AASLD/IDSA for Treating Interferon-Ineligible Patients With Genotype 1 HCV Infection

    Paul Y. Kwo MD - 10/9/2014    3 comments / Last Comment: 10/24/2014
    Historically, evaluating patients for interferon eligibility was critical. Today, interferon-free regimens are evolving and soon they will be standard practice for even the most difficult-to-treat disease.